Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

AstraZeneca’s Farxiga met primary endpoint in Phase 3 heart failure trial 

By Brian Buntz | May 5, 2022

AstraZenecaAstraZeneca’s (LON:AZN) SGLT2 inhibitor Farxiga (dapagliflozin) led to a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular death or worsening heart failure in the DELIVER Phase 3 study. 

First FDA approved in 2014 as a type 2 diabetes treatment, Farxiga has scored approvals related to heart failure and chronic kidney disease. 

AstraZeneca now says that data from the DELIVER and DAPA-HF Phase 3 studies show its efficacy in heart failure regardless of ejection fraction. 

In the two studies, the safety profile of Farxiga was consistent with prior data.

Farxiga’s biggest competitor is Jardiance (empagliflozin) from Boehringer Ingelheim and Eli Lilly, first approved in 2014 for type 2 diabetes. Jardiance now has two FDA indications related to heart failure.

Another competitor is the heart failure drug Entresto (sacubitril/valsartan) from Novartis, which had $2.8 billion in sales in 2021

In 2021, Farxiga generated approximately $3 billion in overall revenue. Jardiance sales were about half as much. 

The DELIVER trial focused on patients with heart failure with mildly reduced or preserved ejection fraction. 

According to CDC, roughly 6.2 million adults in the U.S. have heart failure. 

AstraZeneca notes that about half of heart failure patients have mildly reduced or preserved ejection fraction and limited treatment options. 

“We are delighted to have met the primary endpoint in this patient population, which has few treatment options,” said Dr. Scott Solomon, principal investigator of the DELIVER Phase 3 study. “DELIVER is the largest and broadest trial to date in heart failure with mildly reduced or preserved ejection fraction. The results of DELIVER extend the benefit of dapagliflozin to the full spectrum of patients with heart failure.”

AstraZeneca plans on sharing results from the DELIVER study at an upcoming medical conference and will file for expanded regulatory authorization later this year.


Filed Under: Cardiovascular
Tagged With: AstraZeneca, Entresto, Farxiga, Jardiance
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Janssen
Janssen reports positive clinical trial data for its Xarelto to treat PAD effects
Lilly/Boehringer
FDA approves Lilly’s Jardiance for heart failure 
Pfizer
Pfizer accuses former employees of trade secret theft
Pfizer-Ionis
Pfizer and Ionis halt vupanorsen program after meeting primary endpoint in dyslipidemia study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50